The Bioprocess Revolution: How Technology and Trends are Reshaping Pharmaceutical Manufacturing

Monday, March 17, 2025

The pharmaceutical bioprocess equipment and services market is undergoing a profound transformation, driven by technological advancements, increasing demand for biologics, and a shift towards more efficient and flexible manufacturing processes. This rapidly evolving landscape is reshaping the way biopharmaceuticals are produced, promising improved efficiency, reduced costs, and faster time-to-market for life-saving drugs.

Market Overview and Growth Projections

The global biopharmaceutical processing equipment and consumables market, valued at $36.38 billion in 2023, is on a trajectory of remarkable growth. Industry analysts project that this market will reach $75.72 billion by 2031, growing at a compound annual growth rate (CAGR) of 9.5% from 2024 to 2031.¹ This substantial growth is fueled by several factors, including the rising adoption of biopharmaceuticals, increased outsourcing of biopharmaceutical manufacturing, and accelerated developments in personalized therapies.

The bioprocess technology market, a closely related sector, is experiencing even more dramatic growth. Estimated at $30.7 billion in 2024, it is projected to expand at an impressive CAGR of 14.8%, potentially reaching $121.9 billion by 2034.⁵ This rapid growth underscores the increasing importance of bioprocess technologies in the pharmaceutical industry and highlights the significant investments being made in this field.

Technological Trends Reshaping the Industry

Several key technological trends are driving innovation and efficiency in the bioprocess equipment and services market:

Single-Use Bioprocessing Systems

One of the most significant shifts in recent years has been the widespread adoption of single-use bioprocessing technologies. These systems, which utilize disposable components such as bags, tubing, and filters, offer numerous advantages over traditional stainless-steel bioreactors. The benefits include reduced risk of cross-contamination, increased flexibility in scaling production, and faster setup times.⁶

The single-use bioprocessing market is experiencing rapid growth, with projections indicating an increase from $28.45 billion in 2023 to $128.24 billion by 2033.³ This exponential growth reflects the industry’s recognition of the efficiency and cost-effectiveness offered by single-use systems, particularly for small-batch or clinical-scale production where flexibility and speed are crucial.

Continuous Bioprocessing

Continuous bioprocessing represents a paradigm shift from traditional batch processing methods. This approach enables uninterrupted production of biopharmaceuticals, resulting in reduced batch-to-batch variability, improved product consistency, and lower production costs.⁶ The continuous bioprocessing market, valued at $201 million in 2022, is expected to grow at a remarkable CAGR of 22.4%, reaching $599 million by 2028.¹¹ The adoption of continuous bioprocessing is particularly evident in upstream processes, with many companies implementing continuous perfusion systems. Industry leaders such as Danaher Corporation, Sartorius AG, and Merck KGaA have introduced innovative automated perfusion systems and bioreactors to support this trend.¹¹

Automation and Digital Biomanufacturing

The integration of automation and digital technologies is revolutionizing bioprocessing. The global market for bioprocess optimization and digital biomanufacturing is expected to grow from $24.3 billion in 2024 to $39.6 billion in the coming years.⁴ This growth is driven by the industry’s focus on improving efficiency, reducing human error, and enabling real-time monitoring and control of bioprocesses.

Automation is considered the hottest area of opportunity for vendors’ new product development departments. It is seen as critical for the continued maturation and optimization of the biopharmaceutical industry.¹⁰ The implementation of automation technologies promises to streamline production processes, enhance consistency, and ultimately reduce costs.

Advanced Filtration Systems

Filtration systems play a crucial role in bioprocessing, and technological advancements in this area are contributing significantly to market growth. In 2024, the filtration systems segment is estimated to account for the largest share (22.3%) of the global biopharmaceutical processing equipment and consumables market.¹ This dominance is attributed to the recurring use of filtration at every step in bioprocessing and ongoing technological advancements in filtration technologies.

Market Trends and Drivers

Several key trends are shaping the pharmaceutical bioprocess equipment and services market:

Rising Demand for Biologics

The increasing prevalence of chronic diseases and the growing reliance on biologics, including vaccines, monoclonal antibodies, and cell and gene therapies, are driving the need for advanced bioprocessing solutions.9 This trend is expected to continue, fueling demand for innovative equipment and services that can support the production of these complex biopharmaceuticals.

Expansion of Biopharmaceutical Manufacturing Capacity

A large number of pharmaceutical companies and contract manufacturing organizations (CMOs) are expanding their manufacturing capacities to meet the growing demand for biopharmaceuticals. This expansion is driving increased demand for bioprocessing equipment and consumables for commercial bioproduction.¹

Focus on Process Intensification

The industry is increasingly focused on process intensification, which aims to improve productivity and reduce costs. This approach often involves the use of high-cell-density cultures and perfusion systems, which can significantly increase product yields. For instance, modern bioreactors can achieve titers of 5–10 g L−1, making a 2000 L bioreactor as productive as a 20000 L bioreactor from 20 years ago.²

Growth in Emerging Markets

The expansion of pharmaceutical production sites and existing facilities in emerging markets is driving growth in the bioprocess technology market. These regions are becoming increasingly important hubs for biopharmaceutical manufacturing, creating new opportunities for equipment and service providers.⁵

Regulatory Trends

The regulatory landscape for biopharmaceutical manufacturing continues to evolve, with a focus on ensuring product quality and patient safety while also promoting innovation:

Support for Continuous Manufacturing

Regulatory agencies, including the U.S. Food and Drug Administration (FDA), have shown support for continuous manufacturing processes. This endorsement is encouraging more companies to explore and implement continuous bioprocessing technologies.¹¹

Quality by Design (QbD) Approach

Regulators are increasingly emphasizing the importance of Quality by Design principles in biopharmaceutical manufacturing. This approach encourages manufacturers to build quality into their processes from the outset, which aligns well with the capabilities offered by advanced bioprocessing equipment and automation technologies.

Accelerated Approval Pathways

The introduction of accelerated approval pathways for certain biopharmaceuticals, particularly for rare diseases and unmet medical needs, is driving demand for flexible and scalable bioprocessing solutions that can support rapid development and manufacturing.

Breakthrough Technologies

Several breakthrough technologies are poised to further revolutionize the bioprocess equipment and services market:

3D Bioprinting

The integration of 3D bioprinting technologies is opening new possibilities in tissue engineering and personalized medicine. This technology could potentially transform the production of complex biological structures and tissues for research and therapeutic applications.

Gene Editing and Synthetic Biology

Advancements in gene editing technologies, such as CRISPR-Cas9, are enabling the development of more efficient cell lines for biopharmaceutical production. These technologies, combined with synthetic biology approaches, are expected to significantly enhance the capabilities of bioprocessing systems.

Artificial Intelligence and Machine Learning

The application of AI and machine learning in bioprocessing is improving process optimization, predictive maintenance, and quality control. These technologies are enabling more intelligent and adaptive manufacturing processes, potentially leading to significant improvements in efficiency and product quality.

Market Outlook

The outlook for the pharmaceutical bioprocess equipment and services market is highly positive, with several factors contributing to its continued growth and evolution:

Increasing Investment in R&D

The biopharmaceutical sector’s annual R&D spending is now 8.1 times greater than the aerospace and defense industries, demonstrating a strong commitment to technological advancement and innovation.¹² This substantial investment is likely to drive the development of next-generation biomanufacturing technologies and solutions.

Strategic Partnerships and Industry Consolidation

The market is witnessing increased strategic partnerships and industry consolidation as companies seek to enhance their capabilities and market presence. These collaborations are focused on developing novel therapeutic solutions and optimizing biotechnology process capabilities.¹²

Challenges and Opportunities

While the market outlook is generally positive, there are challenges to be addressed. The high capital investment required for implementing advanced bioprocessing technologies, particularly continuous bioprocessing systems, may pose a barrier for smaller players.¹¹ However, this challenge also presents opportunities for equipment leasing, shared manufacturing facilities, and other innovative business models.

Regional Growth Prospects

The Asia Pacific market is expected to grow at the highest CAGR in the coming years, driven by increasing investments in biopharmaceutical manufacturing infrastructure and growing demand for biologics in the region.¹¹ Meanwhile, the United States continues to lead the upstream bioprocessing market, supported by strong FDA regulations and rapid technology adoption.⁹

In conclusion, the pharmaceutical bioprocess equipment and services market is at the forefront of a technological revolution in biopharmaceutical manufacturing. Driven by innovations in single-use systems, continuous bioprocessing, automation, and digital technologies, the industry is poised for significant growth and transformation. As these technologies continue to evolve and mature, they promise to deliver more efficient, flexible, and cost-effective solutions for the production of life-saving biopharmaceuticals. The coming years are likely to see continued innovation, strategic collaborations, and market expansion, further cementing the critical role of bioprocessing technologies in the future of pharmaceutical manufacturing.

Citations

About the Author

Mike Auerbach, Group Editor-in-Chief, Pharma Group, American Pharmaceutical Review

Publication Detail

This article appeared in American Pharmaceutical Review - Innovations at Interphex 2025 Supplement

Pages: 13-15

Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from American Pharmaceutical Review delivered to your inbox!
Sign up now!